Dr. Mary B. Daly on When to Screen Patients With a Family History of Cancer

Article

Mary B. Daly, MD, PhD, from Fox Chase Cancer Center, discusses the proper timing for screening patients with a family history of cancer.

Mary B. Daly, MD, PhD, professor, chair, Department of Clinical Genetics, Timothy R. Talbot Jr. Chair for Cancer Research, Fox Chase Cancer Center, discusses the proper timing for screening patients with a family history of cancer.

Recent Videos
5 experts in this video
5 experts in this video
Image of a woman with a white shirt in front of an Oncology Nursing News branded backdrop
Photo of a man with glasses in a suit in front of an Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Related Content
Side profile anatomical rendering of a person, with breast tissue and a breast tumor in orange

Vepdegestrant Meets PFS End Point for Metastatic Breast Cancer Subtype

Ashley Chan
March 25th 2025
Article
The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

Lindsay Fischer
November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Line illustration of an IV drip in gold on a dark blue background

FDA Approves Denosumab Biosimiliars for Prior Authorized Indications

Tim Cortese
March 13th 2025
Article

Two denosumab biosimilars have been approved by the FDA for all previously approved uses for the reference drugs in cancers and osteoporosis.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

Line illustration of a breast with tissue on a cerulean background

Frontline Camizestrant Combo Increases PFS In Breast Cancer Subtypes

Kyle Doherty
March 5th 2025
Article

Camizestrant with a CDK4/6 inhibitor was well tolerated and effective as first-line therapy for patients with ESR1-mutated, HR-positive/HER2-negative advanced breast cancer.

Image of a calendar with a thumb tack stuck on a day reading "20," and a stethoscope lying on the calendar, with an image of a clock overlaying

Opinion: Oncology Nurses Can Ease the Burden of Time Toxicity in Cancer Care

Amanda Brink, DNP, APRN, FNP-BC, AOCNP
February 26th 2025
Article

Similar to financial toxicity, time toxicity can have a profound impact on a patient’s quality of life.